Residual chromosomal damage after radiochemo-therapy with and without amifostine detected by 24-color FISH

Strahlentherapie und Onkologie

Volumn 179, Issue 7, 2003, Pages 493-498

  Kuechler, Alma ^a   Dreidax, Mareike ^a   Pigorsch, Steffi U ^b   Liehr, Thomas ^a   Claussen, Uwe ^a   Wendt, Thomas G ^a   Dunst, Jürgen ^b  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

24 color FISH; Amifostine; Radiation induced chromosomal aberrations; Residual chromosomal damage

Indexed keywords

AMIFOSTINE; FLUOROURACIL; RADIOPROTECTIVE AGENT;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHROMOSOME ABERRATION; CHROMOSOME BREAKAGE; CHROMOSOME INVERSION; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DICENTRIC CHROMOSOME; DRUG EFFECT; DRUG INFUSION; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; INTESTINE INJURY; LYMPHOCYTE CULTURE; METAPHASE; MITOSIS; PERIPHERAL LYMPHOCYTE; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE CARE; RADIATION DOSE; RADIATION MUTAGENESIS; RADIATION PROTECTION; RECIPROCAL CHROMOSOME TRANSLOCATION; RECTUM CANCER; SIDE EFFECT; SKIN TOXICITY;

EID: 0038747944     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-003-1095-z     Document Type: Article

References (31)

1. Auletta JJ, Shurin S. Improved hematopoiesis using amifostine in secondary myelodysplasia. J Pediatr Hematol Oncol 1999;21:531-4.
2. Bauchinger M. Retrospective dose reconstruction of human radiation exposure by FISH/chromosome painting. Mutat Res 1998;404:89-96.
3. Bauchinger M, Salassidis K, Braselmann H, et al. FISH-based analysis of stable translocations in a Techa River population. Int J Radiat Biol 1998;73:605-12.
4. Bauchinger M, Schmid E, Braselmann H. Time-course of translocation and dicentric frequencies in a radiation accident case. Int J Radiat Biol 2001;77:553-7.
5. Bisht KS, Prabhu S, Devi PU. Modification of radiation induced damage in mouse intestine by WR-2721. Indian J Exp Biol 2000;38:669-74.
6. Buntzel J, Kuttner K, Frohlich D, Glatzel M. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Ann Oncol 1998;9:505-9.
7. Devi PU, Bisht KS, Vinitha M. A comparative study of radioprotection by Ocimum flavonoids and synthetic aminothiol protectors in the mouse. Br J Radiol 1998;71:782-4.
8. Dunst J, Neubauer S, Becker A, Gebhart E. Chromosomal in-vitro radio-sensitivity of lymphocytes in radiotherapy patients and AT-homozygotes. Strahlenther Onkol 1998;174:510-6.
9. Dunst J, Semlin S, Pigorsch S, Muller AC, Reese T. Intermittent use of amifostine during postoperative radiochemotherapy and acute toxicity in rectal patients. Strahlenther Onkol 2000;176:416-21.
10. Gebhart E, Neubauer S, Schmitt G, Birkenhake S, Dunst J. Use of a three-color chromosome in situ suppression technique for the detection of past radiation exposure. Radiat Res 1996;145:47-52.
11. Gershkevitsh E, Hildebrandt G, Wolf U, Kamprad F, Realo E, Trott KR. Chromosomal aberration in peripheral lymphocytes and doses to the active bone marrow in radiotherapy of prostate cancer. Strahlenther Onkol 2002;178:36-42.
12. Huber R, Braselmann H, Kulka U, Schumacher-Georgiadou V, Bayerl A, Molls M, Bauchinger M. Follow-up analysis of translocation and dicentric frequencies, measured by FISH-chromosome painting in breast cancer patients after partial-body radiotherapy with little bone marrow exposure. Mutat Res 1999;446:103-9.
13. Kleinerman RA, Littlefield LG, Tarone RE, Machado SG, Blettner M, Peters LJ, Boice JO Jr. Chromosome aberrations in peripheral lymphocytes and radiation dose to active bone marrow in patients treated for cancer of the cervix. Radiat Res 1989;119:176-90.
14. Kuechler A, Neubauer S, Grabenbauer GG, Claussen U, Liehr T, Sauer R, Wendt TG. Is 24-color FISH detection of in-vitro radiation-induced chromosomal aberrations suited to determine individual intrinsic radiosensitivity? Strahlenther Onkol 2002;178:209-15.
15. Lemke J, Claussen J, Michel S, Chudoba I, Muhlig P, Westermann M, Sperling K, Rubtsov N, Grummt UW, Ullmann P, Kromeyer-Hauschild K, Liehr T, Claussen U. The DNA-based structure of human chromosome 5 in interphase. Am J Hum Genet 2002;71:1051-9.
16. List AF, Heaton R, Glinsmann-Gibson B, Capizzi RL. Amifostine stimulates formation of multipotent and erythroid bone marrow progenitors. Leukemia 1998;12:1596-602.
17. Mothersill C, Seymour C. Radiation-induced bystander effects: past history and future directions. Radiat Res 2001;155:759-67.
18. Neubauer S, Dunst J, Gebhart E. The impact of complex chromosomal rearrangements on the detection of radiosensitivity in cancer patients. Radiother Oncol 1997;43:189-95.
19. Provinciali M, Ciavattini A, Oi Stefano G, Argentati K, Garzetti GG. In vivo amifostine (WR-2721) prevents chemotherapy-induced apoptosis of peripheral blood lymphocytes from cancer patients. Life Sci 1999;64:1525-32.
20. Savage JRK, Simpson PJ. On scoring of FISH "painted" chromosome exchange aberrations. Mutat Res 1994;307:345-53.
21. Savage JRK, Simpson PJ. FISH "painting" pattern resulting from complex exchanges. Mutat Res 1994;312:51-60.
22. Schmidberger H, Virsik-Koepp P, Rave-Frank M, Reinosch KR, Pradier O, Munzel U, Hess CF. Reciprocal transtocations in patients with testicular seminoma before and after radiotherapy. Int J Radiat Oncol Biol Phys 2001;50:857-64.
23. Schröck E, du Manoir S, Veldman T, et al. Multicolor spectral karyotyping of human chromosomes. Science 1996;273:4947.
24. Spath-Schwalbe E, Lange C, Genvresse I, Kruger L, Eucker J, Schweigert M, Sezer O, Budach V, Possinger K. Influence of amifostine on toxicity of CHOP in elderly patients with aggressive non-Hodgkin's lymphoma - a phase II study. Anticancer Drugs 2002;13:395-403.
25. Speicher MR, Gwyn Ballard S, Ward OC. Karyotyping human chromosomes by combinatorial multi-fluor FISH. Nat Genet 1996;12:368-75.
26. Spencer CM, Goa KL. Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector. Drugs 1995;50:1001-31.
27. Trog D, Bank P, Wendt TG, Koscielny S, Beleites E. Daily amifostine given concomitantly to chemoradiation in head and neck cancer. A pilot study. Strahlenther Onkot 1999;175:444-9.
28. Verdorfer I, Neubauer S, Letzel S, Angerer J, Arutyunyan R, Martus P, Wucherer M, Gebhart E. Chromosome painting for cytogenetic monitoring of occupationally exposed and non-exposed groups of human individuals. Mutat Res 2001;491:97-109.
29. Verma RS, Babu A. Human chromosomes - manual of basic techniques. New York-Oxford-Beijing-Frankfurt-Sao Paulo-Sydney-Tokyo-Toronto: Pergamon Press, 1989.
30. Wasserman T, Mackowiak JI, Brizel OM, Dster W, Zhang J, Peeples PJ, Sauer R. Effect of amifostine on patient assessed clinical benefit In irradiated head and neck cancer. Int J Radiar Oncol Biol Phys 2000;48:1035-9.
31. Wasserman TH, Brizel OM. The role of amifostine as a radioprotector [Review]. Oncology (Huntingt) 2001;15:1349-54, discussion 1357-60.